- Home
- GLAD vs SVRA Comparison
GLAD vs SVRA Comparison
Compare GLAD & SVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLAD
- SVRA
- Stock Information
- Founded
- GLAD 2001
- SVRA 2007
- Country
- GLAD United States
- SVRA United States
- Employees
- GLAD N/A
- SVRA N/A
- Industry
- GLAD Finance/Investors Services
- SVRA Biotechnology: Pharmaceutical Preparations
- Sector
- GLAD Finance
- SVRA Health Care
- Exchange
- GLAD Nasdaq
- SVRA Nasdaq
- Market Cap
- GLAD 571.4M
- SVRA 528.3M
- IPO Year
- GLAD N/A
- SVRA N/A
- Fundamental
- Price
- GLAD $28.51
- SVRA $2.39
- Analyst Decision
- GLAD Hold
- SVRA Buy
- Analyst Count
- GLAD 1
- SVRA 5
- Target Price
- GLAD $23.00
- SVRA $5.60
- AVG Volume (30 Days)
- GLAD 75.9K
- SVRA 1.4M
- Earning Date
- GLAD 08-04-2025
- SVRA 08-11-2025
- Dividend Yield
- GLAD 6.99%
- SVRA N/A
- EPS Growth
- GLAD 17.67
- SVRA N/A
- EPS
- GLAD 3.93
- SVRA N/A
- Revenue
- GLAD $92,932,000.00
- SVRA N/A
- Revenue This Year
- GLAD N/A
- SVRA N/A
- Revenue Next Year
- GLAD $12.10
- SVRA N/A
- P/E Ratio
- GLAD $7.26
- SVRA N/A
- Revenue Growth
- GLAD N/A
- SVRA N/A
- 52 Week Low
- GLAD $21.40
- SVRA $1.89
- 52 Week High
- GLAD $30.43
- SVRA $5.11
- Technical
- Relative Strength Index (RSI)
- GLAD 75.48
- SVRA 53.01
- Support Level
- GLAD $27.75
- SVRA $1.98
- Resistance Level
- GLAD $27.33
- SVRA $2.50
- Average True Range (ATR)
- GLAD 0.47
- SVRA 0.17
- MACD
- GLAD 0.15
- SVRA 0.05
- Stochastic Oscillator
- GLAD 98.38
- SVRA 78.85
About GLAD Gladstone Capital Corporation
Gladstone Capital Corp is an externally managed, closed-end, non-diversified management investment company. Its investment objectives are to, achieve and grow current income by investing in debt securities of established businesses that would provide stable earnings and cash flow to pay expenses, make principal and interest payments on its outstanding indebtedness, and make distributions to stockholders that grow over time; and provide its stockholders with long-term capital appreciation in the value of its assets by investing in equity securities of established businesses that can grow over time to permit it to sell its equity investments for capital gains.
About SVRA Savara Inc.
Savara Inc is a biopharmaceutical company. It is focused on rare respiratory diseases. The company's program, molgramostim nebulizer solution (molgramostim), is an inhaled granulocyte-macrophage colony-stimulating factor in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). It has one segment specialty pharmaceuticals within the respiratory system.